The emerging research on psychedelics as a treatment for resistant depression is examined, highlighting both their potential benefits and associated risks. Studies indicate that substances such as psilocybin and MDMA may provide new avenues for individuals whose depression has not responded to traditional therapies. These psychedelics could assist in resetting neural pathways, offering relief from chronic symptoms. However, it is crucial to carefully consider the risks, including psychological side effects. Continued research is essential to fully understand the therapeutic potential of psychedelics in the treatment of resistant depression.
Track 18-1 Safety and Efficacy of Psychedelics in Treatment-Resistant Depression
Track 18-2 The Role of Psychedelics in Modulating Brain Connectivity
Track 18-3 Comparing Traditional Antidepressants with Psychedelic Therapy
Track 18-4 Long-Term Effects of Psychedelic-Assisted Therapy
Track 18-5 Regulatory and Legal Framework for Psychedelic Use in Mental Health
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
